Drug Trial Radar · NCT06409936
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Last checked: Nov 20, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Jun 26, 2025
Primary completion
Jun 2029
Study completion Jun 2032
Sponsor
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'AdultoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Grupo Español de Leucemia Mieloide Crónica
- First posted
- May 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2, interventional, randomized unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in combination with nilotinib 300 mg BID (arm B). All patients in both arm A and arm B will be treated for a minimum of 2 years (core phase). If they will have achieved a DMR (MR4), or if it will be in the interest of the patient, the treatment will be continued. During the consolidation phase (2 years) asciminib will be continued at the same dose in both arms; in the combination arm the nilotinib dose will be reduced to 300 mg daily. The patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment (TFR phase). The rate of TFR at 5 year (1 year after discontinuation) will be evaluated.
Conditions
- CML, Chronic Phase
- Chronic Myeloid Leukemia, Chronic Phase
- Chronic Myeloid Leukemia, BCR/ABL-Positive
- Chronic Myeloid Leukemia
Interventions
AsciminibDrug
both arms will include asciminib treatment
NilotinibDrug
in the arm B the nilotinib will be added on in all patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- evaluation of response of asciminib single-agent or in combination with nilotinibTime frame: at 2 years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Hospital del Mar (Barcelona)
Barcelona, Spain · Recruiting
Hospital Universitario Basurto
Bilbao, Spain · Recruiting
Institut Català d'Oncologia Girona
Girona, Spain · Recruiting
Hospital Virgen de las Nieves
Granada, Spain · Recruiting
Hospital Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, Spain · Recruiting
Hospital Gral U. Gregorio Marañón
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain · Recruiting
Complejo Asistencial Universitario de Salamanca
Salamanca, Spain · Recruiting
Hospital Universitario La Fe Valencia
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.